Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Clinical effects of comprehensive treatments for FIGO Stage IIB adenocarcinoma/adenosquamous carcinoma of the cervix
Ying Yao1, †, Le Chen1, †, Huiying Yu2, Hongyun Xiang3, Jing Yao4, Jie Tang1, *
1 Department of Gynecologic Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
2 Department of Obstetrics and Gynecology, the First Hospital of Chenzhou, the affiliated Hospital of University of South China, Chenzhou, China
3 Department of Obstetrics and Gynecology, Jingzhou People’s Hospital, the affiliated Hospital of University of South China, Jingzhou, China
4 Department of Obstetrics and Gynecology, the First Hospital of Loudi, the affiliated Hospital of University of South China, Loudi, China
† Contributed equally.
Eur. J. Gynaecol. Oncol. 2018, 39(4), 579–584; https://doi.org/10.12892/ejgo4179.2018
Published: 10 August 2018
To evaluate the clinical effects of comprehensive treatments for the FIGO Stage IIB adenocarcinoma (AC) / adenosquamous carcinoma (ASC) of cervix of patients from four institutions between 2000 and 2009 with Stage IIB AC/ASC of cervix that were included and divided into two groups. Both groups received initial cisplatin-based neoadjuvant chemotherapy (NACT) treatment. Radical surgery (RS, n=70) group subsequently underwent surgery followed by adjuvant chemo-radiotherapy, while the radiotherapy (RT, n=70) group received the standard concurrent chemo-radiotherapy alone. Differences in outcomes were compared. Multivariate analysis was used. The overall survival (OS) was 74.3% vs. 52.9% (p = 0.002) and progression free survival (PFS) rates were 64.3% vs. 44.3 %( p = 0.007) in each group. Complications in the RS group were acceptable. Presence of lymph node metastasis was a significant factor in determining OS. The authors conclude that NACT combined with RS followed by adjuvant chemo-radiotherapy is a promising treatment option for Stage IIB AC/ASC of the cervix.
FIGO stage IIB